EDMONTON, ALBERTA -- (MARKET WIRE) -- November 28, 2006 -- ViRexx Medical Corp. (TSX: VIR) (AMEX: REX), a company focused on the development of immunotherapies for certain cancers, chronic hepatitis B & C and embolotherapy for tumors, today announced the Company has prioritized its research activities to focus on the completion of its existing pipeline products that provide near term potential revenue streams.
